PMID- 31229451 OWN - NLM STAT- MEDLINE DCOM- 20200721 LR - 20231213 IS - 1873-7064 (Electronic) IS - 0028-3908 (Print) IS - 0028-3908 (Linking) VI - 157 DP - 2019 Oct TI - Altered amygdala DNA methylation mechanisms after adolescent alcohol exposure contribute to adult anxiety and alcohol drinking. PG - 107679 LID - S0028-3908(19)30237-0 [pii] LID - 10.1016/j.neuropharm.2019.107679 [doi] AB - Binge drinking during adolescence increases the risk for neuropsychiatric disorders including alcoholism in adulthood. DNA methylation in post-mitotic neurons is an important epigenetic modification that plays a crucial role in neurodevelopment. We examined the effects of intermittent ethanol exposure during adolescence on adult behavior and whether DNA methylation changes provide a plausible explanation for the lasting effects of this developmental insult. One hour after last adolescent intermittent ethanol (AIE), growth arrest and DNA damage inducible protein 45 (Gadd45a, Gadd45b, and Gadd45g) mRNA expression was increased and DNA methyltransferase (DNMT) activity and Dnmt3b expression was decreased in the amygdala as compared to adolescent intermittent saline (AIS) rats. However, AIE rats 24 h after last exposure displayed increased DNMT activity but normalized Gadd45 and Dnmt3b mRNA expression compared to AIS rats. In adulthood, rats exposed to AIE show increased Dnmt3b mRNA expression and DNMT activity, along with decreased Gadd45g mRNA expression in the amygdala. DNA methylation of neuropeptide Y (Npy) and brain-derived neurotrophic factor (Bdnf) exon IV is increased in the AIE adult amygdala compared to AIS adult rats. Treatment with the DNMT inhibitor 5-azacytidine (5-azaC) at adulthood normalizes the AIE-induced DNA hypermethylation of Npy and Bdnf exon IV with concomitant reversal of AIE-induced anxiety-like and alcohol-drinking behaviors. These results suggest that binge-like ethanol exposure during adolescence leads to dysregulation in DNA methylation mechanisms in the amygdala which may contribute to behavioral phenotypes of anxiety and alcohol use in adulthood. CI - Published by Elsevier Ltd. FAU - Sakharkar, Amul J AU - Sakharkar AJ AD - Center for Alcohol Research in Epigenetics, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA; Jesse Brown Veterans Affairs Medical Center, Chicago, IL, 60612, USA. FAU - Kyzar, Evan J AU - Kyzar EJ AD - Center for Alcohol Research in Epigenetics, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA; Jesse Brown Veterans Affairs Medical Center, Chicago, IL, 60612, USA. FAU - Gavin, David P AU - Gavin DP AD - Center for Alcohol Research in Epigenetics, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA; Jesse Brown Veterans Affairs Medical Center, Chicago, IL, 60612, USA. FAU - Zhang, Huaibo AU - Zhang H AD - Center for Alcohol Research in Epigenetics, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA; Jesse Brown Veterans Affairs Medical Center, Chicago, IL, 60612, USA. FAU - Chen, Ying AU - Chen Y AD - Center for Alcohol Research in Epigenetics, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA. FAU - Krishnan, Harish R AU - Krishnan HR AD - Center for Alcohol Research in Epigenetics, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA; Jesse Brown Veterans Affairs Medical Center, Chicago, IL, 60612, USA. FAU - Grayson, Dennis R AU - Grayson DR AD - Center for Alcohol Research in Epigenetics, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA. FAU - Pandey, Subhash C AU - Pandey SC AD - Center for Alcohol Research in Epigenetics, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, 60612, USA; Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, 60612, USA; Jesse Brown Veterans Affairs Medical Center, Chicago, IL, 60612, USA. Electronic address: scpandey@uic.edu. LA - eng GR - F30 AA024948/AA/NIAAA NIH HHS/United States GR - R01 AA010005/AA/NIAAA NIH HHS/United States GR - U24 AA024605/AA/NIAAA NIH HHS/United States GR - R01 AA025035/AA/NIAAA NIH HHS/United States GR - P50 AA022538/AA/NIAAA NIH HHS/United States GR - IK2 BX001650/BX/BLRD VA/United States GR - I01 BX000143/BX/BLRD VA/United States GR - I01 BX004091/BX/BLRD VA/United States GR - U01 AA019971/AA/NIAAA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20190620 PL - England TA - Neuropharmacology JT - Neuropharmacology JID - 0236217 RN - 0 (Antigens, Differentiation) RN - 0 (Bdnf protein, rat) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Cell Cycle Proteins) RN - 0 (Gadd45a protein, rat) RN - 0 (Gadd45b protein, rat) RN - 0 (Intracellular Signaling Peptides and Proteins) RN - 0 (Neuropeptide Y) RN - 3K9958V90M (Ethanol) RN - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase 1) RN - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferases) RN - EC 2.1.1.37 (Dnmt1 protein, rat) RN - M801H13NRU (Azacitidine) SB - IM MH - Age Factors MH - Alcohol Drinking/*physiopathology MH - Amygdala/*metabolism MH - Animals MH - Antigens, Differentiation/biosynthesis MH - Anxiety/chemically induced/*physiopathology MH - Azacitidine/pharmacology MH - Brain-Derived Neurotrophic Factor/metabolism MH - Cell Cycle Proteins/biosynthesis MH - DNA (Cytosine-5-)-Methyltransferase 1/metabolism MH - DNA (Cytosine-5-)-Methyltransferases/biosynthesis MH - DNA Methylation/*physiology MH - Ethanol/antagonists & inhibitors/*pharmacology MH - Exons/drug effects MH - Intracellular Signaling Peptides and Proteins/biosynthesis MH - Male MH - Neuropeptide Y/metabolism MH - Rats MH - DNA Methyltransferase 3B MH - GADD45 Proteins PMC - PMC6681823 MID - NIHMS1039920 OTO - NOTNLM OT - Adolescent binge drinking OT - Alcohol use disorders OT - Amygdala OT - Anxiety OT - BDNF OT - DNA methylation/demethylation OT - Neuropeptide Y COIS- Conflict of interest Authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2019/06/24 06:00 MHDA- 2020/07/22 06:00 PMCR- 2020/10/01 CRDT- 2019/06/24 06:00 PHST- 2018/12/04 00:00 [received] PHST- 2019/06/08 00:00 [revised] PHST- 2019/06/18 00:00 [accepted] PHST- 2019/06/24 06:00 [pubmed] PHST- 2020/07/22 06:00 [medline] PHST- 2019/06/24 06:00 [entrez] PHST- 2020/10/01 00:00 [pmc-release] AID - S0028-3908(19)30237-0 [pii] AID - 10.1016/j.neuropharm.2019.107679 [doi] PST - ppublish SO - Neuropharmacology. 2019 Oct;157:107679. doi: 10.1016/j.neuropharm.2019.107679. Epub 2019 Jun 20.